Gate Bioscience expands Lilly deal to target hard-to-drug proteins

Gate Bioscience has expanded its collaboration and licence agreement with Eli Lilly, adding at least one further target to the companies' existing joint programme in molecular gate therapeutics. The deal could be worth more than $870 million to the California-based biotech, subject to the achievement of preclinical, clinical, and commercial milestones.

Under the revised terms, Gate will receive an upfront payment and a further payment if the option to add a second target is exercised. Lilly will take an exclusive worldwide licence to research, develop, manufacture, and commercialise any medicines arising from the collaboration for the selected targets. Gate retains responsibility for early discovery work, while Lilly leads later-stage preclinical development, clinical development, and commercialisation.

What are molecular gates?

Molecular gates are orally available small molecules that selectively eliminate target proteins by blocking their transit through the Sec61 secretory channel, directing them instead towards degradation. Gate positions the approach as capable of reaching proteins that are considered undruggable by conventional methods, including those for which no current therapy exists or where patients currently rely on injectable biologics.

The company says its platform can, in principle, engage approximately 4,000 such targets across immunology, neuroscience, and cardiometabolic disease. Gate is backed by a syndicate that includes Forbion, Versant Ventures, Andreessen Horowitz, GV, and ARCH Venture Partners, alongside Lilly itself.

Co-founder and chief executive Jordi Mata-Fink said the expansion "reflects Lilly's confidence in that engine and in the team behind it," adding that the collaboration has already demonstrated the platform's ability to deliver selective molecular gates systematically.

Market context and competitive read-across

Targeted protein degradation has become one of the most actively contested areas in drug discovery. Established modalities such as PROTACs and molecular glues have attracted substantial capital and partnership interest from large pharmaceutical companies, with a number of programmes now in clinical-stage development. Molecular gates operate through a mechanistically distinct route, exploiting the Sec61 translocon rather than the ubiquitin-proteasome system used by PROTACs, which may confer advantages in selectivity or in reaching targets that lack suitable E3 ligase proximity. Whether that distinction translates into durable clinical differentiation remains to be demonstrated.

Lilly's willingness to deepen the relationship is a meaningful signal. The company has been one of the more active large-cap pharma investors in platform-stage biotechs, and an expansion of an existing collaboration, rather than a new partnership, typically indicates satisfactory progress in the underlying science. Gate has not yet disclosed which specific targets are covered by the expanded agreement, nor which therapeutic areas are prioritised under the new work, limiting the ability to assess the clinical risk profile at this stage.

For Gate, the arrangement preserves its wholly owned pipeline while providing non-dilutive capital and access to Lilly's development and commercial infrastructure. The company said it will continue advancing its proprietary portfolio in parallel. Investors will watch for disclosure of the first named target, preclinical data packages, and any signal on the timeline to an investigational new drug filing.